Mucin-1 (CA 15-3 Antigen)

Subscribe to Selected New Research on Mucin-1

1734 relevant articles (15 outcomes, 145 trials/studies) found for this Bio-Agent

Description: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.

Also Known As:

CA 15-3 Antigen; Epithelial Membrane Antigen; Antigens, CD227; CA 15.3 Antigen; CD227 Antigen; Antigen CA 15 3; Antigen, CA 15-3; Antigen, CA 15.3; Antigen, CA-15-3; Antigen, CD227; Antigen, Epithelial Membrane; CA 15 3 Antigen; CA-15-3, Antigen; CD227 Antigens; Membrane Antigen, Epithelial; Mucin 1; Mucin, Muc1; Mucin, Polymorphic Epithelial; Antigen CA-15-3; CA-15-3 Antigen; Episialin; Epithelial Mucin, Polymorphic; Muc1 Mucin; Polymorphic Epithelial Mucin

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 931

Biological Markers: 21607

Biological Tumor Markers: 3444

Carbohydrate Tumor-Associated Antigens: 238

Mucin-1: 1734

CAM 123-6 antigen: 3

MUC1 tandem repeat peptide: 3

human MUC1 protein: 1

human (950-958) MUC-1 protein

human MUC-X protein

rat MUC1 protein

Differentiation Antigens: 874

CD Antigens: 32

Mucin-1: 1734

CAM 123-6 antigen: 3

MUC1 tandem repeat peptide: 3

human MUC1 protein: 1

human (950-958) MUC-1 protein

human MUC-X protein

rat MUC1 protein

Experts

1.	Paszkiewicz-Gadek, A: 3 articles (01/2008 - 01/2000)
2.	Kohno, Nobuoki: 3 articles (12/2007 - 07/2005)
3.	Porowska, H: 2 articles (01/2008 - 02/2003)
4.	Yokoyama, Akihito: 2 articles (06/2007 - 07/2005)
5.	Hansson, Gunnar C: 2 articles (08/2006 - 12/2003)
6.	Gindzieński, A: 2 articles (02/2003 - 01/2000)
7.	Koukourakis, M I: 2 articles (01/2002 - 01/2000)
8.	Giatromanolaki, A: 2 articles (01/2002 - 01/2000)
9.	Pecher, G: 2 articles (09/2001 - 09/2000)
10.	Segal-Eiras, A: 2 articles (01/2001 - 01/2000)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2006 - "Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC." 06/01/2006 - "Previous studies from this laboratory reported mucin-1 (MUC1)-driven expression of NIS in cancer cells. " 08/06/2002 - "In the present study, NMR methods were used to correlate the effects of cryptic glycosylation outside of the PDTRP core epitope region to the recognition and binding of a monoclonal antibody, Mab B27.29, raised against the intact tumor-associated MUC1 mucin. " 11/01/1987 - "[Immunohistochemical study of new monoclonal antibodies--E29, 115D8 --to an epithelial membrane antigen (EMA) in ovarian tumors]" 06/15/2009 - "The mucin 1 (MUC1) oncoprotein is aberrantly overexpressed by approximately 90% of human breast cancers. " Order ALL the reference details at left...
2.	Carcinoma (Carcinomatosis) 08/01/2001 - "OBJECTIVE: To investigate the efficacy of discovery of cervical lymph nodes micrometastasis of supraglottic carcinomas by detection of mucin (MUC1) gene. " 02/16/2005 - "OBJECTIVE: To study the relationship of abnormal expression of mucin 1 with the invasiveness of breast carcinoma cells. " 10/01/2003 - "This study indicates that osteoid formation and negative expression of epithelial membrane antigen are key features in the differentiation from metastatic carcinoma." 02/01/1997 - "Clinical studies are currently underway to assess the biodistribution and therapeutic potential of the genetically engineered human antibody hCTM01 directed against polymorphic epithelial mucin (PEM) in patients with ovarian carcinoma. " 05/01/1987 - "[An immunohistochemical study of the distribution of epithelial membrane antigen (EMA) in uterine carcinoma]" Order ALL the reference details at left...
3.	Adenocarcinoma 05/01/1998 - "Clinical diagnosis of adenocarcinoma was suspected but the pathological study showed an anaplastic morphology, with little plasmacytic differentiation and lack of stain with cytokeratins and epithelial membrane antigen (EMA), immunohistochemical marker of plasmatic cells, among others. " 06/15/2007 - "Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma." 05/01/2006 - "Human polymorphic epithelial mucin (MUC1) is a heavily glycosylated large protein that is frequently overexpressed on the surface of many human adenocarcinomas. " 07/01/2005 - "Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis." 11/01/2002 - "Membrane-associated mucin MUC1 is expressed in various adenocarcinoma cells and active T lymphocytes. " Order ALL the reference details at left...
4.	Chordoma 12/01/2008 - "Positivity for both epithelial membrane antigen and AE1/AE3 had a sensitivity of 90% and a specificity of 100% for detecting chordoma in this study. " 05/01/1998 - "Thus, positive staining with epithelial membrane antigen and the identification of a large number of rough endoplasmic reticulum-mitochondrial complexes are suggestive of metastatic chordoma. " 09/01/1987 - "Demonstration of cytokeratins and an epithelial membrane antigen in chondroid chordoma." 11/01/1985 - "Demonstration of cytokeratins and an epithelial membrane antigen in chordomas and human fetal notochord." 01/01/1994 - "The immunohistochemical staining pattern (cytokeratin negative, epithelial membrane antigen (EMA) negative) can be helpful in distinguishing it from chordoma with chondroid differentiation (cytokeratin positive, EMA positive). " Order ALL the reference details at left...
5.	Mesothelioma 06/01/1988 - "For the differentiation between reactive mesothelial cells and malignant mesothelioma human milk fat globule and/or epithelial membrane antigen, in this study proved to be most reliable, their presence strongly indicating malignancy. " 03/01/2005 - "The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study." 02/25/2003 - "The detection of long microvilli, an ultrastructural feature unique for malignant epithelial mesothelioma, requires immunolabeling of epithelial membrane antigen to be visible by light microscopy. " 05/01/1992 - "Corresponding microvilli can be visualized by immunostaining for epithelial membrane antigen in both cell block preparations from effusions and biopsy specimens, allowing the identification of malignant mesothelioma. " 03/01/1988 - "Expression of epithelial membrane antigen on malignant mesothelioma cells. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Keratins (Keratin)
2.	Vimentin
3.	S100 Proteins (S 100 Protein)
4.	Carcinoembryonic Antigen
5.	Antibodies
6.	Antigens
7.	Glycoproteins (Glycoprotein)
8.	Cyclooxygenase 2 (Cyclooxygenase-2)
9.	celecoxib (Celebrex)
10.	gemcitabine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Immunotherapy
4.	Radioimmunotherapy
5.	Microspheres (Microsphere)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>